Published in Am J Transl Res on October 10, 2012
Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 5.43
Macrophages and therapeutic resistance in cancer. Cancer Cell (2015) 1.95
An Immune Atlas of Clear Cell Renal Cell Carcinoma. Cell (2017) 1.49
The role of complement in tumor growth. Adv Exp Med Biol (2014) 1.11
Tissue-resident macrophages: then and now. Immunology (2015) 1.10
Angiogenic capacity of M1- and M2-polarized macrophages is determined by the levels of TIMP-1 complexed with their secreted proMMP-9. Blood (2013) 1.03
Longitudinal PET imaging of muscular inflammation using 18F-DPA-714 and 18F-Alfatide II and differentiation with tumors. Theranostics (2014) 0.95
Myeloid derived suppressor cells: Targets for therapy. Oncoimmunology (2013) 0.94
HPV infection: immunological aspects and their utility in future therapy. Infect Dis Obstet Gynecol (2013) 0.89
Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. Sci Rep (2016) 0.88
Dual targeted immunotherapy via in vivo delivery of biohybrid RNAi-peptide nanoparticles to tumour-associated macrophages and cancer cells. Adv Funct Mater (2015) 0.88
Melanoma-derived factors alter the maturation and activation of differentiated tissue-resident dendritic cells. Immunol Cell Biol (2015) 0.87
Modeling putative therapeutic implications of exosome exchange between tumor and immune cells. Proc Natl Acad Sci U S A (2014) 0.87
Radiation and inflammation. Semin Radiat Oncol (2015) 0.86
An optimized disaggregation method for human lung tumors that preserves the phenotype and function of the immune cells. J Leukoc Biol (2014) 0.86
The overlapping roles of antimicrobial peptides and complement in recruitment and activation of tumor-associated inflammatory cells. Front Immunol (2015) 0.83
Autoimmunity as a double agent in tumor killing and cancer promotion. Front Immunol (2014) 0.83
Electrolytic valving isolation of cell co-culture microenvironment with controlled cell pairing ratios. Analyst (2014) 0.83
The redox biology network in cancer pathophysiology and therapeutics. Redox Biol (2015) 0.83
Critical Role of Tumor Microenvironment in Shaping NK Cell Functions: Implication of Hypoxic Stress. Front Immunol (2015) 0.82
Innate immune regulation by STAT-mediated transcriptional mechanisms. Immunol Rev (2014) 0.81
Interplay between Cellular and Molecular Inflammatory Mediators in Lung Cancer. Mediators Inflamm (2016) 0.81
Hypoxia promotes glioma-associated macrophage infiltration via periostin and subsequent M2 polarization by upregulating TGF-beta and M-CSFR. Oncotarget (2016) 0.81
Hepatocellular carcinoma is accelerated by NASH involving M2 macrophage polarization mediated by hif-1αinduced IL-10. Oncoimmunology (2016) 0.81
Small cell lung cancer: Recruitment of macrophages by circulating tumor cells. Oncoimmunology (2015) 0.80
A Systematic Approach to Identify Markers of Distinctly Activated Human Macrophages. Front Immunol (2015) 0.80
Stemness and plasticity of lung cancer cells: paving the road for better therapy. Onco Targets Ther (2014) 0.80
Extended culture of macrophages from different sources and maturation results in a common M2 phenotype. J Biomed Mater Res A (2015) 0.79
How to target small cell lung cancer. Oncoscience (2015) 0.78
Unique roles of Akt1 and Akt2 in IGF-IR mediated lung tumorigenesis. Oncotarget (2016) 0.78
Dual role of macrophages in the response of C26 colon carcinoma cells to 5-fluorouracil administration. Oncol Lett (2016) 0.78
Cancer Stem Cells and Their Microenvironment: Biology and Therapeutic Implications. Stem Cells Int (2017) 0.77
Icmt inhibition exerts anti-angiogenic and anti-hyperpermeability activities impeding malignant pleural effusion. Oncotarget (2016) 0.77
Pancreatic Cancer Cell Exosome-Mediated Macrophage Reprogramming and the Role of MicroRNAs 155 and 125b2 Transfection using Nanoparticle Delivery Systems. Sci Rep (2016) 0.77
Proangiogenic TIE2(+)/CD31 (+) macrophages are the predominant population of tumor-associated macrophages infiltrating metastatic lymph nodes. Mol Cells (2013) 0.77
Tumor-associated macrophages: implications in cancer immunotherapy. Immunotherapy (2017) 0.76
Characterization of M1/M2 Tumour-Associated Macrophages (TAMs) and Th1/Th2 Cytokine Profiles in Patients with NSCLC. Cancer Microenviron (2015) 0.76
Cancer: A Tale of Aberrant PRR Response. Front Immunol (2014) 0.76
Cancer-associated fibroblasts promote an immunosuppressive microenvironment through the induction and accumulation of protumoral macrophages. Oncotarget (2016) 0.75
Dual polarization of human alveolar macrophages progressively increases with smoking and COPD severity. Respir Res (2017) 0.75
Translational research in thoracic surgery-the National Taiwan University Hospital experience. J Thorac Dis (2016) 0.75
Tumor-Associated Macrophage (TAM) and Angiogenesis in Human Colon Carcinoma. Open Access Maced J Med Sci (2015) 0.75
Acute myeloid leukemia cells polarize macrophages towards a leukemia supporting state in a Growth factor independence 1 dependent manner. Haematologica (2016) 0.75
In vitro inflammatory effects of hard metal (WC-Co) nanoparticle exposure. Int J Nanomedicine (2016) 0.75
Leukocyte-mediated Delivery of Nanotherapeutics in Inflammatory and Tumor Sites. Theranostics (2017) 0.75
Monocytic myeloid-derived suppressor cells as a potent suppressor of tumor immunity in non-small cell lung cancer. Oncol Lett (2016) 0.75
The function of cancer-shed gangliosides in macrophage phenotype: involvement with angiogenesis. Oncotarget (2016) 0.75
The Role of Myeloid-Derived Suppressor Cells in Viral Infection. Viral Immunol (2017) 0.75
Interferon-γ Promotes Antibody-mediated Fratricide of Acute Myeloid Leukemia Cells. J Biol Chem (2016) 0.75
Antigen processing and immune regulation in the response to tumours. Immunology (2016) 0.75
The Crosstalk between Ovarian Cancer Stem Cell Niche and the Tumor Microenvironment. Stem Cells Int (2017) 0.75
Salmonella-Mediated Cancer Therapy: Roles and Potential. Nucl Med Mol Imaging (2016) 0.75
The Dr. Jekyll and Mr. Hyde complexity of the macrophage response in disease. J Leukoc Biol (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Inflammation and cancer. Nature (2002) 53.78
Cancer-related inflammation. Nature (2008) 34.21
Exploring the full spectrum of macrophage activation. Nat Rev Immunol (2008) 26.08
Monocyte and macrophage heterogeneity. Nat Rev Immunol (2005) 24.36
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 23.99
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol (2002) 17.85
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 15.45
Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer (2004) 14.55
Macrophage diversity enhances tumor progression and metastasis. Cell (2010) 13.41
Alternative activation of macrophages: mechanism and functions. Immunity (2010) 12.43
Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19
Cancer and the chemokine network. Nat Rev Cancer (2004) 10.27
Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med (2001) 9.99
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol (2010) 9.59
Distinct role of macrophages in different tumor microenvironments. Cancer Res (2006) 9.29
Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell (2005) 9.06
CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell (2009) 8.54
The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol (2002) 8.27
Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 7.76
A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res (2004) 7.56
The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer (2008) 7.40
Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol (2010) 6.85
Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res (2007) 6.60
Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res (2006) 6.52
Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol (2011) 6.34
Tumor angiogenesis. Adv Cancer Res (1985) 5.66
Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer (2006) 5.60
Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res (1996) 5.38
CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell (2009) 5.22
IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol (2011) 5.11
Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat Immunol (2009) 4.76
Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res (2004) 4.74
Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res (2010) 4.25
A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One (2009) 3.86
The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev (2008) 3.33
CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell (2011) 3.31
Obstacles and opportunities for understanding macrophage polarization. J Leukoc Biol (2011) 3.16
Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol (2008) 2.76
Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med (2009) 2.73
Immunotherapy: past, present and future. Nat Med (2003) 2.62
Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-gamma- and CD40L-mediated costimulation. J Leukoc Biol (2005) 2.50
Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res (2010) 2.48
Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol (2011) 2.45
Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med (2011) 2.39
The macrophage growth factor CSF-1 in mammary gland development and tumor progression. J Mammary Gland Biol Neoplasia (2002) 2.37
Visualizing stromal cell dynamics in different tumor microenvironments by spinning disk confocal microscopy. Dis Model Mech (2008) 2.34
Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer (2008) 2.32
Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammation. J Leukoc Biol (2004) 2.30
Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol (2004) 2.26
Pivotal Advance: Tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE₂ catabolism in myeloid cells. J Leukoc Biol (2010) 2.22
Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol (2009) 2.19
Role of macrophages in tumour progression. Immunol Lett (2009) 2.07
The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer (2010) 2.03
M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol (2011) 2.02
Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res (2003) 1.89
Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol (2005) 1.87
Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood (2007) 1.83
Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J (2009) 1.80
Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. Blood (2007) 1.74
Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer. Eur Respir J (2007) 1.73
Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors. Am J Pathol (2010) 1.70
Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors. J Immunol (2009) 1.64
Granulocyte macrophage colony-stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages. Cancer Res (2009) 1.57
Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice. Cancer Res (2009) 1.51
Identification of a common gene signature for type II cytokine-associated myeloid cells elicited in vivo in different pathologic conditions. Blood (2006) 1.43
High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer. Br J Cancer (2008) 1.41
An ets2-driven transcriptional program in tumor-associated macrophages promotes tumor metastasis. Cancer Res (2010) 1.39
Tumor-associated macrophage infiltration in pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. Oncology (1999) 1.38
Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self. Biochim Biophys Acta (1988) 1.36
The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer. BMC Cancer (2010) 1.30
The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma. Histopathology (2009) 1.28
Effective cancer therapy through immunomodulation. Annu Rev Med (2006) 1.26
Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin Cancer Res (2011) 1.24
Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated. J Invest Dermatol (2011) 1.24
TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer. Am J Respir Crit Care Med (2007) 1.24
Stromal macrophage expressing CD204 is associated with tumor aggressiveness in lung adenocarcinoma. J Thorac Oncol (2010) 1.12
Increased IL-10 mRNA expression in tumor-associated macrophage correlated with late stage of lung cancer. J Exp Clin Cancer Res (2011) 1.10
Prostaglandin E₂ signaling and bacterial infection recruit tumor-promoting macrophages to mouse gastric tumors. Gastroenterology (2010) 1.10
Tumor-associated macrophages provide a suitable microenvironment for non-small lung cancer invasion and progression. Lung Cancer (2011) 1.10
M2 polarized macrophages and giant cells contribute to myofibrosis in neuromuscular sarcoidosis. Am J Pathol (2011) 1.05
Inflammation and breast cancer. Microenvironmental factors regulating macrophage function in breast tumours: hypoxia and angiopoietin-2. Breast Cancer Res (2007) 1.04
M2-polarized tumor-associated macrophages are associated with poor prognoses resulting from accelerated lymphangiogenesis in lung adenocarcinoma. Clinics (Sao Paulo) (2011) 1.03
Infiltrating immune cells, but not tumour cells, express FasL in non-small cell lung cancer: No association with prognosis identified in 3-year follow-up. Int J Cancer (2003) 1.02
Immunocytochemical localization of latent transforming growth factor-beta1 activation by stimulated macrophages. J Cell Physiol (1999) 1.01
Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer. Int J Cancer (2012) 0.97
Mononuclear phagocyte heterogeneity in cancer: different subsets and activation states reaching out at the tumor site. Immunobiology (2011) 0.96
Clinical significance of VEGF-C status in tumour cells and stromal macrophages in non-small cell lung cancer patients. Br J Cancer (2004) 0.96
Chemokine receptor expression in tumour islets and stroma in non-small cell lung cancer. BMC Cancer (2010) 0.95
Expression of macrophage-derived chemokine (MDC)/CCL22 in human lung cancer. Cancer Immunol Immunother (2006) 0.94
Association of macrophages, mast cells and eosinophil leukocytes with angiogenesis and tumor stage in non-small cell lung carcinomas (NSCLC). Lung Cancer (2004) 0.92
Aberrant PGE₂ metabolism in bladder tumor microenvironment promotes immunosuppressive phenotype of tumor-infiltrating myeloid cells. Int Immunopharmacol (2011) 0.90
CD8+ T cells expressing IL-10 are associated with a favourable prognosis in lung cancer. Lung Cancer (2010) 0.85
Tumour necrosis factor-alpha expression in tumour islets confers a survival advantage in non-small cell lung cancer. BMC Cancer (2010) 0.83
T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFβ) signaling mediate superior tumor regression in an animal model of adoptive cell therapy. J Transl Med (2012) 0.81
Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res (2008) 2.26
Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol (2008) 1.63
Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery. Proc Natl Acad Sci U S A (2012) 1.40
Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway. Cancer Res (2011) 1.34
Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. Prostate (2009) 1.14
Neutrophils recruit regulatory T-cells into tumors via secretion of CCL17--a new mechanism of impaired antitumor immunity. Int J Cancer (2014) 0.94
Generation of antigen-presenting cells from tumor-infiltrated CD11b myeloid cells with DNA demethylating agent 5-aza-2'-deoxycytidine. Cancer Immunol Immunother (2009) 0.94
Bcl-2 mediated modulation of vascularization in prostate cancer xenografts. Prostate (2009) 0.86
Adenoviral-based immunotherapy provides local disease control in an orthotopic murine model of esophageal cancer. J Immunother (2014) 0.81
The timing of TGF-β inhibition affects the generation of antigen-specific CD8+ T cells. BMC Immunol (2013) 0.78